New! Sign up for our free email newsletter.
Science News
from research organizations

Long-acting antipsychotic therapy plus cognitive training show promise for schizophrenia

Patients who received the combination therapy had increased cognition and functioning

Date:
November 19, 2020
Source:
University of California - Los Angeles Health Sciences
Summary:
Scientists have found that the use of long-acting antipsychotic medication combined with the use of cognitive training in group settings led to improved cognition and increased productivity.
Share:
FULL STORY

UCLA scientists and colleagues found the use of long-acting antipsychotic medication combined with the use of cognitive training in group settings led to improved cognition and increased productivity.

Researchers say patients using a combination of long-acting antipsychotic medication and a multipronged cognitive remediation that taught memory and problem-solving skills had significant improvements in work and school function.

Schizophrenia is a serious mental illness that affects how a person thinks, feels and behaves. People with schizophrenia may appear to have lost touch with reality, which can cause distress for family and friends and lead to permanent disability. Treatments delivered in a sustained manner can help people with schizophrenia engage in school or work, achieve independence and enjoy personal relationships.

During a 12-month randomized controlled trial, 60 patients from the UCLA Aftercare Program who recently experienced a first episode of schizophrenia were randomized to oral or long-acting injectable antipsychotic medication and to either cognitive remediation or healthy behavior training. Cognitive remediation involved training in attention, memory, and problem-solving skills to help navigate complex, life-like situations. The healthy behavior training focused on nutrition, stress management, and exercise, with equal treatment time. All patients were provided supported employment and education to encourage return to work or school.

Systematic cognitive training, when combined with consistent antipsychotic medication adherence, achieved in this case through the use of a long-acting medication, can significantly improve cognitive deficits in the initial period of schizophrenia. These therapies show a separate significant impact on improving work and school functioning.

UCLA researchers included: Keith Nuechterlein, Joseph Ventura, Kenneth Subotnik, Denise Gretchen-Doorly, Luana Turner, Laurie Casaus, John Luo, Michael Boucher and Jacqueline Hayata. Morris Bell of Yale University and Alice Medalia of Columbia University also collaborated in the study.

The research is published in the journal Psychological Medicine.

A grant from the National Institute of Mental Health funded this research.


Story Source:

Materials provided by University of California - Los Angeles Health Sciences. Note: Content may be edited for style and length.


Journal Reference:

  1. Keith H. Nuechterlein, Joseph Ventura, Kenneth L. Subotnik, Denise Gretchen-Doorly, Luana R. Turner, Laurie R. Casaus, John Luo, Michael L. Boucher, Jacqueline N. Hayata, Morris D. Bell, Alice Medalia. A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning. Psychological Medicine, 2020; 1 DOI: 10.1017/S0033291720003335

Cite This Page:

University of California - Los Angeles Health Sciences. "Long-acting antipsychotic therapy plus cognitive training show promise for schizophrenia." ScienceDaily. ScienceDaily, 19 November 2020. <www.sciencedaily.com/releases/2020/11/201119153948.htm>.
University of California - Los Angeles Health Sciences. (2020, November 19). Long-acting antipsychotic therapy plus cognitive training show promise for schizophrenia. ScienceDaily. Retrieved March 28, 2024 from www.sciencedaily.com/releases/2020/11/201119153948.htm
University of California - Los Angeles Health Sciences. "Long-acting antipsychotic therapy plus cognitive training show promise for schizophrenia." ScienceDaily. www.sciencedaily.com/releases/2020/11/201119153948.htm (accessed March 28, 2024).

Explore More

from ScienceDaily

RELATED STORIES